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Background: Laparoscopic prostatectomy (LRP) may activate clotting system influencing the risk of perioperative
thrombosis in patients with prostate cancer. Moreover, different anaesthetic techniques can also modify coagulant
factors. Thus, the aim of this study was to investigate the effects on pro- and anti-coagulant and fibrinolytic factors
of two established types of anaesthesia in patients with prostate cancer undergoing elective LRP.
Methods: 102 patients with primary prostate cancer, who underwent conventional LRP or robot-assisted laparoscopic
prostatectomy (RALP), were studied and divided into 2 groups to receive total intravenous anesthesia with
target-controlled infusion (TIVA-TCI) or balanced inhalation anaesthesia (BAL) prior to surgery. Before the induction of
anaesthesia (T0), 1 hr (T1) and 24 hrs post-surgery (T2), some pro-coagulant factors, fibronolysis markers, p-selectin and
haemostatic system inhibitors were evaluated.
Results: Both TIVA-TCI and BAL patients showed a marked and significant increase in pro-coagulant factors and
consequent reduction in haemostatic system inhibitors in the early post operative period (p ≤ 0.004 for each markers).
Use of RALP showed a significant increase in prothrombotic markers as compared to LRP. In TIVA patients undergoing
LRP, a significant reduction of p-selectin levels between T0 and T2 (p = 0.001) was observed as compared to BAL,
suggesting a better protective effect on platelet activation of anaesthetic agents used for TIVA.
Conclusions: Both anaesthetic techniques significantly seem to increase the risk of thrombosis in prostate cancer
patients undergoing LRP, mainly when the robotic device was utilized, encouraging the use of a peri-operative
thromboembolic prophylaxis in these patients.
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Several epidemiological studies have shown that a strong
correlation exists between cancer and haemostatic system
[1-4]. The interaction between cancer and the coagulation
system perturbs and stimulates pro-coagulant activity,
consequently inducing a pro-thrombotic state [5] and
increasing the risk of thromboembolic disease (TED)
[6]. Interestingly in cancer patients a systemic activation* Correspondence: forastiere@ifo.it
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the absence of TED [2,7].
Cancer cells can activate the clotting system directly,
thereby generating thrombin, or indirectly by stimulating
mononuclear cells, platelets and endothelial cells to
synthesize and express a variety of procoagulants [8].
The consequent formation of a fibrin matrix appears to
promote tumor growth by favoring neoangiogenesis
and shielding tumor cells against attack from immuno-
competent cells [5]. Thrombin also works as a potent
promoter of cancer growth and spread via an increase
in tumor cell adhesion [9]. Some biomarkers have beend. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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during the course of cancer disease. Associations between
elevated levels and future TED have been found for
D-Dimer, prothrombin fragment 1 + 2 (F1 + 2), thrombin-
antithrombin complexes (TAT), plasminogen activator
inhibitor type 1 (PAI-1), clotting factor VIII (FVIII) and
soluble P-selectin [10]. These markers, not sufficiently
validated in patients undergoing different intraoperative
anaesthetic regimens, reflect different steps of the coagula-
tion cascade (Figure 1). In particular, F1 + 2 is released
when activated factor X cleaves prothrombin into active
thrombin and the fragment formation is a key event in the
coagulation cascade. The formation of TAT complexes
represents an indirect measure for the activation of
the coagulatory system, because is the first amount of
thrombin that binds to antithrombin (AT). Elevated
FVIII levels are a well-established risk factor for first
manifestation and for recurrence of TED. PAI-1 is a
potent inhibitor of the fibrinolytic system while d-dimer is
a stable end product of fibrin degradation and is elevated
by enhanced fibrin formation and fibrinolysis [10-12].
P-selectin, a member of cell adhesion molecules, is re-
leased from the α-granules of activated platelets and
from Weibel-Palade bodies of endothelial cells. P-selectin
plays a crucial role in thrombogenesis and induces a
prothrombotic state by the adhesion of platelets and
leukocytes to cancer cells. Levels of soluble P-selectin
are elevated in patients with acute TED [13].
Surgical tissue trauma also leads to an increased risk
of TED [14] even though the incidence of TED is closely
related to the organ involved. The tumor sites most atFigure 1 Coagulation cascade. The solid lines indicate a activating functirisk of developing TED seem to be the pancreas, brain,
and stomach [14]. In patients with advanced prostate
cancers, the incidence of TED is controversial, ranging
from 0.5% to 40% in the first month after surgery
[3,15-17]. The increased risk of TED in prostate cancer
patients undergoing radical prostatectomy recommends
administering a pharmacologic anti-thrombotic prophy-
laxis [18-22], though the latter may cause an increase in
intra-operative bleeding [23,24] .
To date, factors influencing the risk of perioperative
thrombosis in patients undergoing prostate cancer sur-
gery have not been identified yet. At present, we do not
know whether, in addition to the risk factors already
known, the use of different techniques of anesthesia may
increase the risk of thrombosis in cancer patients under-
going surgery. Therefore, the main aim of this prospective
study was to investigate changes in the markers most
sensitive to detecting activation of the haemostatic system
in patients with prostate cancer undergoing elective laparo-
scopic prostatectomy with two different intra-operative
anaesthetic regimens, target-controlled infusion (TIVA-TCI)
and balanced inhalation anaesthesia (BAL). A secondary
aim was to evaluate whether using a robot device in the
laparoscopic prostatectomy influences the effect of differ-
ent anesthetic techniques applied.
Methods
Patient population
Between October 2009 and June 2012, 400 consecutive
patients with primary prostate cancer, undergoing gen-
eral anaesthesia and conventional laparoscopic radicalon, while the dashed lines a inhibitory action.
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tatectomy (RALP), were considered eligible for the study
(Figure 2). This study was approved by the Ethics Com-
mittee of the Regina Elena National Cancer Institute,
Rome (Prot.CE/550), and a written informed patient
consent was obtained from all participants. Protocol was
registered in Clinical trials.gov (NCT01998685). The
inclusion criteria for the study were a newly diagnosed
cancer of the prostate with histological Gleason score
evaluation. Exclusion criteria included: (a) ASA >2, (b)
metabolic equivalent task < 4, (c) BMI > 30, (d) no pre-
operative pharmacological thromboprophylaxis and/or
anti-coagulant therapy, (e) history of abnormal bleeding,
or abnormal coagulant factors, (f ) sepsis within the last
2 weeks, (g) previous new adjuvant treatments (chemo,
hormone, and radiotherapy), (h) non-steroid, anti-inflam-
matory and statin drugs for at least 2 wks before surgery,
(i) venous or arterial thromboembolism within the last
3 months, peripheral venous disease, (l) neurological dis-
ease with extremity paresis, (m) chronic liver disease, (n)
pre-operative haemoglobin concentration < 9 mg dl−1, (o)
prolonged duration of surgery (>3 hrs); (p) peri-operative
blood transfusion, (q) inadequate material for laboratory
testing. One exclusion criterion sufficed exclusion.
Out of the 400 patients with primary prostate cancer
who underwent laparoscopic prostatectomy, 244 were
excluded from the study for the following reasons: 218
for ASA ≥ 3, 4 for previous new adjuvant treatments, 22
for anti-inflammatory and statin therapy before surgery.Figure 2 Design of the study: patient selection.Thus, 156 patients with primary prostate cancer consti-
tuted the patient population of this randomized study
and were alternatively divided into 2 groups to receive
TIVA-TCI or BAL anaesthesia prior to surgery. Then, a
further 54 patients were excluded: 9 for a prolonged dur-
ation of surgery, 5 for intra-operative blood transfusion
and 40 for inadequate blood samples. Finally, 102 patients
with primary prostate cancer comprised the patient popu-
lation of the study: 54 received TIVA-TCI and 48 BAL
anesthesia prior to surgery.
All patients with high-risk prostate cancer (according
to Guidelines on Prostate Cancer of European Association
of Urology, 2012) underwent LRP with extended pelvic
lymph node dissection. Patients with intermediate risk
underwent LRP or RALP .
Anesthetic protocol
The patients did not receive premedication. In the
TIVA-TCI group, anaesthesia was induced with propofol
(DiprivanTM, ASTRA-Zeneca, Milano, Italy) 6 μg ml−1 and
remifentanyl (UltivaTM, GlaxoSmith-Kline AB, Verona,
Italy) 0.4-1 μg kg−1 min, simultaneously administered using
two separate modules of a continuous computer-assisted
TCI system. Anaesthesia was maintained with propofol
4 μg ml−1 and remifentanil 0.25 μg Kg−1 min. This infusion
was modified by 0.05 μg kg−1 min steps according to anal-
gesic needs. In the BAL group, anaesthesia was induced
with midazolam (Hameln pharmaceuticals Gmbh, Hameln,
Germany) 0.1 mg kg−1 and fentanyl (FentanestTM, Pftzer,
Latina, Italy) 1.5 μg kg−1 Anaesthesia was maintained with
sevoflurane (SevoraneTM, Abbott, Latina, Italy) 2.0% , oxy-
gen 40% and air 70% with positive pressure ventilation in a
circle system, in order to achieve normocapnia.
In both groups, cisatracurium besylate (NimbexTM,
Glaxo Smith Kline) 0.1-0.5 mg kg−1 was given to facilitate
orotracheal intubation with a cuffed tube, followed by
the continuous application of 0.06-0.12 mg kg−1 h−1 via
infusion pumps. Pneumoperitoneum was created by intra-
peritoneal insufflation of CO2 with an insufflation pressure
of 13–15 mmHg and patient in the supine position.
Patients were then placed in the steep Trendelenburg
position (30° from horizontal). Intraperitoneal pressure was
maintained at 15 mmHg during the induced pneumoperi-
toneum. A routine anaesthesia monitoring was performed
on all patients (Table 1).
During anaesthesia all patients received warm venous
infusion of saline solution (0.9% NaCl) 3 ml Kg −1 h−1 and
thermal mattresses. Systolic arterial pressure was main-
tained at 100 mm Hg or 70% of the preoperative value.
Hypotension was treated with crystalloid fluid infusion or
intravenous boluses of ephedrine.
After surgery the residual neuromuscular blockade was
reversed with a mixture of atropine (Galenica Senese,
Siena, Italy) 1.5 mg and neostigmine (IntrastigminaTM,
Table 1 Clinical characteristics and peri-operative data of
patients with prostate cancer who underwent surgery







Age (yrs) 60.66 (5.91) 62.16 (6.23) 0.31
Venous thromboembolism risk
Highest risk 54 (100%) 48 (100%) 1
Prostate cancer risk*
Intermediate-risk 26 (48.1%) 30 (62.5%)
High-risk 28 (51.8%) 18 (37.5%) 0.17
ASA, n (%):
I 4 (7.4%) 6 (12.5%)
II 50 (92.6%) 42 (87.5%) 0.39
Histological grade of cancer
G2 (Gleason 5–6) 15 (27.8%) 14 (29.2)
G3 (Gleason 7–10) 39 (72.2%) 34 (70.8%) 0.88
pT, n (%)
2 30 (55.6%) 32 (66.7%) 0.25
3 24 (44.4%) 16 (33.3%)
pN, n (%) #
0 17 (85.0%) 24 (96.0%) 0.20
1 3 (15.0%) 1 (4.0%)
Peri-operative data
Type of surgery
LRP 36 (66.7%) 34 (70.8%) 0.65
RALP 18 (33.3%) 14 (29.2%)
Time of anaesthesia (min) 107.5 (16.8) 101.4 (26.2) 0.26
Blood loss (ml) 123.3 (131.1) 121.4 (110.6) 0.81
Total amount of crystalloid
received (ml)
468.5 (110.21) 496.8 (198.5) 0.27
Intra-operative body
temperature
36.2 (0.3) 36.1 (0.2) 0.83
Intra-operative MAP (mmHg) 104.6 (10.5) 106.2 (10.2) 0.61
Intra-operative SpO2 (%) 96.7 (0.9) 97.8 (1.8) 0.75
Arterial lactate level (mmol/l)
1 h post-surgery 0.7 (0.2) 0.6 (0.4) 0.32
24 h post-sugery 1.7 (0.2) 1.8 (0.2) 0.82
Intra-operative BE (mmol/l) 0.3 (0.4) 0.4 (0.4) 0.62
Intra-operative PaO2 (mmHg) 219.4 (11.2) 216.5 (16.8) 0.72
Values are expressed in absolute values or mean (SD).
Abbreviations: TIVA-TCI total intravenous anaesthesia with target-controlled
infusion, BAL balanced inhalation anaesthesia, LRP conventional laparoscopic
radical prostatectomy, RALP robot-assisted laparoscopic prostatectomy.
*According to Guidelines on Prostate Cancer, European Association of
Urology, 2012.
#Lymph node dissection was made in 45 out of 102 pts.
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were switched off, and 100% O2 was given with 8 l min
fresh gas flow for 1 min. In addition, a forced-air warm-
ing blanket was used post-surgery (Equator Covective
Warming TM, Smith Medical Italia, Milano, Italy).
After tracheal extubation all patients received ketoralac
trometamina (Toradol, Recordati, Milano, Italy) 30 mg,
ranitidine (RanidilTM, Menarini, Firenze, Italy) 50 mg
and morphine (Recordati) 2 mg in bolus and then by a
controlled analgesia device (DeltecTM, Smiths Medical
ASD, St Paul, MN).
Clinical parameters
The risk of venous thromboembolism was evaluated
according to the model proposed by Caprini et al. [25]
and Bergqvist et al. [26]. Patients were divided into 4
different levels of risk: low (score 0–1), moderate (score 2),
high (score 3–4), highest (score >4). The following clinical
parameters were also evaluated: (a) global assessment of
anesthetic risk (ASA), (b) grading of prostate cancer
(Gleason score), (c) pathological tumor-node-metastasis
stage, (d) time of surgery, (e) quantity and type of liquids
administered, (f) blood loss, (g) peri-operative complica-
tions such as hypertension, hyperglycemia, hypothermia,
infections and pain (evaluated by a 6-point verbal rating
scale: 0: no pain to 5: most severe pain imaginable).
In all patients, the presence of venous thrombosis by
clinical observation, venous and pelvic ultrasound were
evaluated in the peri-operative period and on days 8 and
21 after surgery.
Prophylaxis anti-thrombosis
Since in most of our patients changes in pro- and anti-
coagulant and fibrinolytic markers were observed in the
peri-operative period, an anti-thrombotic prophylaxis was
made 24 hrs post surgery, for 4 weeks, by using Enoxapar-
ina (ClexaneTM, Sanofi-Aventis, Milano) 4000 UI/die .
Prothrombotic markers
Before the induction of anaesthesia (T0), 1 hr post-surgery
(T1) and 24 hrs post-surgery (T2), the following factors
were evaluated: (a) procoagulant markers: fibrinogen,
TAT, F1 + 2 and FVIII; (b) fibrinolysis markers: PAI-1,
D-dimer; (c) platelet-aggregating properties: p-selectin;
(d) hemostatic system inhibitors: AT, protein C (PC) and
protein S (PS) activity.
Blood samples were collected in tubes without addi-
tives containing 3.2% sodium citrate (Vacutainer, Becton-
Dickinson, Franklin Lakes, NJ USA). Samples were
centrifuged within 1 h at 2500 g for 20 min, to obtain
platelet-poor plasma. The plasmas were immediately
tested. Moreover, plasma and serum samples were sep-
arated and stored in multiple aliquots at −80°C for
subsequent testing. All coagulation parameters (PT,
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by clotting, chromogenic and immunological methods
on fully-automated ACL TOP analyzer using HemosIL®
commercial kits (Instrumentation Laboratory Company,
Bedford, MA USA). Abnormal values were defined by
the clinical laboratory or manufacturer’s assay. Plasma
levels of TAT and F1 + 2 were measured by enzyme-linked
immunosorbent assay Enzygnost® TAT micro and Enzyg-
nost® F1 + 2 mono kits, respectively (Siemens Healthcare
Diagnostics Inc, NY USA), according to the manufacturer’s
instructions. Both assays employ the quantitative sandwich
enzyme immunoassay technique. All samples showing
values above the standard curve were re-tested with
appropriate dilutions. Plasma levels of PAI-1 were mea-
sured with the enzyme-linked immunosorbent assay
Asserachrom® kit (Diagnostica Stago, Asnieres, France),
according to the manufacturer’s instructions. Plasma
p-selectina levels were determined by Human sP-Selectin
enzyme immunoassay (R&D Systems, Inc Minneapolis,
MN USA), according to the manufacturer’s instructions,
employing the quantitative sandwich enzyme immuno-
assay technique.
Statistical analysis
Data were analyzed with Statistical Package for the Social
Sciences (SPSS) 14.0 software. Continuous and categorical
variables were expressed as the mean ± standard deviation
or standard error and as frequency values and propor-
tions, respectively. Pearson’s chi-square test was used
to assess possible differences in dichotomous variables
between the various groups examined. The means of nor-
mally distributed data were compared with the Student’s
t-test. In other cases, the groups were compared with
the Mann-Whitney’s U test. P values of the tests were
adjusted using the Bonferroni method. Paired samples
were analyzed by t-test and Wilcoxon Signed Ranks Test.
Multiple linear regression was used in order to test the
effect of anaesthesia, surgery and clinical characteristics
of patients on changes of prothrombotic markers 24 h
post-surgery (T2 time). A p-value of <0.05 was considered
statistically significant.
Results
Clinical characteristics of the patients
The clinical characteristics of the patients enrolled in the
study are reported in Tables 1 and 2. No significant differ-
ences were observed regarding age between TIVA-TCI
and BAL patients.
Thirty-two out of 102 patients (31.4%) underwent RALP
and were equally distributed between the TIVA-TCI and
BAL. The lymph node dissection was made in 45 out of
102 pts (44.1%).
All patients were at highest risk of venous thrombo-
embolism, according to the model proposed by Capriniet al. [25] and Bergqvist et al. [26] (being all neoplastic
and undergoing surgery); 10 of these (9.8%) had an ASA
I whereas 92 (90.2%) an ASA II.
Thirty-nine patients of TIVA-TCI group (72.2%) and
34 of BAL group (70.8%) showed a high grade prostatic
carcinoma (G3) with Gleason score ≥7.
Patients undergoing LRP showed a locally more advanced
tumor (pT3) as compared to those treated with RALP
(Table 2). No significant differences were observed regard-
ing lymph node involvement (pN). The mean duration
of anesthesia was 103.8 ± 26.1 min, with no differences
between the TIVA-TCI and BAL groups (p = 0.26).
During surgery a light decrease in hematocrit and hemo-
globin concentration was observed in both groups, but
intra-operative blood loss was similar. Also, the volume of
crystalloid administered during anaesthesia was similar
in both groups. Similarly, no statistical differences were
observed regarding hemodynamic and respiratory param-
eters. None of the patients experienced adverse clinical
events during their postoperative course.
In all patients no TED was observed in the post-
operative period and in a 2-yr follow-up. This is probably
due to the anti-thrombotic prophylaxis which was carried
out for ethical reasons in all patients 24 hrs post surgery
because intra-operative changes of some pro-coagulant
markers were observed. Lymph node metastases were
detected in only 4 out of 45 patients with lymph node
dissection (8.9%): one in the TIVA-TCI group and 3 in
the BAL group (p = 0.32).
Types of anaesthesia and prothrombotic markers
Changes of prothrombotic markers associated with the
use of different techniques of anesthesia are reported in
Tables 3 and 4. No statistically significant differences
were observed in the baseline values of biomarkers (at
T0) between TIVA-TCI and BAL groups, even when we
considered the type of surgery. In both TIVA-TCI and
BAL patients a significant and continuous reduction in
screen clotting time PT (given as percentage) was observed
during post-surgery period (T2) as compared to T0
(p = 0.001), while aPTT was shortened at T1 and then
normalised on the first postoperative day (T2).
At the end of surgery (T1), both TIVA-TCI and BAL
patients showed a marked and significant increase in
pro-coagulant factors (TAT, F1 + 2 and FVIII) and con-
sequent reduction in haemostatic system inhibitors (AT,
PC and PS) compared to the values measured prior to
surgery (p ≤ 0.004 for each markers). The greatest increase
was observed in the values of TAT and F1 + 2 (about 3
times compared to T0), while the values of FVIII
increased approximately 30%. F1 + 2 and FVIII slightly
reduced at T2 but remained significantly higher than
basal levels (p ≤ 0.04 for each markers). Only TAT
values returned to pre-anaesthesia values. We observed
Table 2 Clinical characteristics and peri-operative data of patients with prostate cancer, divided in 4 subgroups
according type of anesthesia and surgery
TIVA-TCI LRP (n. 36 pts) TIVA-TCI RALP (n. 18 pts) BAL LRP (n. 34 pts) BAL RALP (n. 14 pts) P
Clinical data
Age (yrs) 61.4 (5.7) 59.5 (6.7) 63.2 (5.8) 60.1 (7.7) 0.25
ASA, n (%):
I 3 (8.3%) 1 (5.6%) 5 (14.7%) 1 (7.1%) 0.68
II 33 (91.7%) 17 (94.4%) 29 (85.3%) 13 (92.9%)
Histological grade of cancer
G2 (Gleason 5–6) 9 (25.0%) 6 (33.3%) 10 (29.4) 4 (28.6) 0.93
G3 (Gleason 7–10) 27 (75.0%) 12 (66.7%) 24 (70.6%) 10 (71.4%)
pT, n (%)
2 12 (33.3%) 18 (100%) 18 (52.9%) 14 (100%) 0.001
3 24 (66.7%) 0 16 (47.1%) 0
pN, n (%)*
0 11 (84.6%) 6 (85.7%) 14 (93.3%) 10 (100%) 0.57
1 2 (15.4%) 1 (14.3%) 1 (6.7%) 0
Perioperative data
Time of anaesthesia (min) 104.0 (21.3) 109.7 (24.4) 98.8 (30.2) 105.2 (24.8) 0.32
Blood loss (ml) 119.2 (140.3) 128.3 (150.1) 118.2 (121.4) 125.2 (131.5) 0.30
Total amount of crystalloid
received (ml)
475.4 (100.4) 460.8 (118.4) 486.1 (166.4) 499.8 (200.2) 0.21
Intra-operative body temperature 36.2 (0.3) 36.1 (0.4) 36.1 (0.2) 36.1 (0.3) 0.87
Intra-operative MAP (mmHg) 103.8 (11.8) 105.3 (12.5) 105.4 (12.4) 106.8 (12.2) 0.54
Intra-operative SpO2 (%) 96.7 (0.9) 96.7 (0.9) 97.8 (1.8) 97.8 (1.8) 0.75
Arterial lactate level (mmol/l)
1 h post-surgery 0.7 (0.2) 0.7 (0.3) 0.6 (0.3) 0.6 (0.4) 0.81
24 h post-sugery 1.8 (0.3) 1.7 (0.2) 1.7 (0.3) 1.8 (0.3) 0.77
Intra-operative BE (mmol/l) 0.3 (0.4) 0.4 (0.3) 0.3 (0.4) 0.4 (0.3) 0.78
Intra-operative PaO2 (mmHg) 220.6 (13.2) 218.8 (13.4) 214.6 (18.6) 219.5 (19.0) 0.22
Values are expressed in absolute values or mean (SD).
Abbreviations: TIVA-TCI total intravenous anaesthesia with target-controlled infusion, BAL balanced inhalation anaesthesia, LRP laparoscopic radical prostatectomy,
RALP robot-assisted laparoscopic prostatectomy.
*Lymph node dissection was made in 45 out of 102 pts.
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that remains significantly lower than prior to surgery
(p = 0.001).
Fibrinogen levels significantly decreased at T1 in com-
parison to the initial values, but rose significantly 24 hours
post-surgery in both groups, showing an increase of about
20-30% as compared to T0 values (p = 0.001).
Changes in pro-coagulant factors and haemostatic
system inhibitors were similar in both TIVA-TCI and
BAL patients with no significant differences between
the two groups of patients. In regards to the fibrinolysis
system, D-dimer concentration in TIVA-TCI group, levels
increased about 6-fold at T1 compared to baseline level
(p = 0.001, Table 3), while in BAL patients it showed an
increase of about 4-fold (p = 0.001, Table 4). Both groups
showed a decrease of D-dimer at T2 even if theconcentration remained higher than baseline levels (p =
0.001), with no significant differences between TIVA-TCI
and BAL patients.
Levels of the PAI-1, the principal inhibitor of the fibrin-
olysis system, and D-dimer remained constant between
T0 and T1 but significantly increased at T2 in both
groups.
Grading of prostate cancer evaluated by Gleason score
and pathological tumor stages showed no significant effects
on changes in prothrombotic markers observed both in the
TIVA and BAL groups. Similarly, it was observed for all
other clinical parameters analyzed.
Surgery and prothrombotic markers
Multivariate analysis demonstrated that only p-selectin
was significantly correlated to the type of anesthesia and
Table 3 Changes of prothrombotic markers in patients with prostate cancer who underwent surgery with total
intravenous anesthesia with target-controlled infusion (TIVA-TCI) before the induction of anaesthesia (T0), 1 hr
post-surgery (T1) and 24 hrs post-surgery (T2)
T0 T1 T2 P
T0 vs T1 T1 vs T2 T0 vs T2
Screen clotting time
- PT (%) 93.1 (1.3) 85.6 (1.2) 82.5 (1.2) 0.001 0.21 0.001
- PTT (sec) 29.6 (0.6) 26.8 (0.7) 27.6 (0.8) 0.003 0.07 0.18
Procoagulant markers
- Fibrinogen (mg/dL) 285.5 (7.1) 262.3 (6.6) 353.3 (8.8) 0.004 0.001 0.001
- TAT (ng/L) 9.1 (1.9) 22.8 (3.2) 9.7 (2.4) 0.002 0.004 0.79
- F1 + 2 (pmol/L) 210.8 (27.3) 622.1 (64.2) 364.4 (45.6) 0.001 0.001 0.007
- FVIII (%) 142.9 (8.1) 194.2 (9.3) 162.3 (5.6) 0.001 0.004 0.04
Fibrinolysis markers
- PAI-1 (ng/ml) 15.2 (1.4) 21.9 (5.8) 36.1 (9.8) 0.41 0.20 0.04
- D-dimer (μg/L) 127.1 (12.8) 721.4 (170.4) 364.2 (28.3) 0.001 0.02 0.001
Haemostatic system inhibitors
- AT (%) 102.1 (1.8) 90.6 (1.9) 87.4 (2.4) 0.001 0.38 0.001
- protein C (%) 109.6 (2.8) 95.4 (2.8) 87.8 (2.8) 0.004 0.03 0.001
- protein S (%) 93.8 (3.1) 84.2 (2.8) 82.4 (2.4) 0.01 0.56 0.001
Platelet-aggregating properties
- p-selectin (ng/ml) 37.9 (2.0) 36.8 (2.4) 33.5 (2.6) 0.78 0.37 0.28
Values are mean (SD).
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TIVA-TCI patients undergoing LRP showed a significant
reduction in p-selectin levels between T0 and T2
(p = 0.001) while no changes were observed in the BAL
group that did not use the robotic device (Figure 3). In
contrast, a significant increase of p-selectin value was
observed in patients undergoing RALP, regardless of the
type of anesthesia, both 1 and 24 hours after surgery.
Patients undergoing RALP showed also 24 hrs after
surgery (T2), at univariate analysis, a greater reduction
of PS, an inhibitor of haemostatic system, as compared
to patients undergoing LRP (p = 0.02) independent of
the type of anaesthesia applied.
Discussion
Results of our study have demonstrated that both anaes-
thetic techniques seem to increase the risk of TED in
prostate cancer patients undergoing LRP, mainly when
the robot device was utilized, suggesting, therefore, the
utility of a peri-operative thromboembolic prophylaxis.
In fact, both TIVA-TCI and BAL patients showed a
marked and significant increase in pro-coagulant factors
and consequent reduction in haemostatic system inhibi-
tors in the early post operative period (p ≤ 0.004 for each
markers). However, this effect could be linked also to
surgical stress, although the latter seems to have an
independent effect only for p-selectin, as demonstratedby multivariate analysis. Moreover, the significant reduc-
tion of p-selectin levels between T0 and T2 (p = 0.001)
observed in TIVA patients undergoing LRP, although
this group of patients was composed mainly of patients
at high-risk prostate cancer (as reported in Table 1),
demonstrated that general anaesthetic agents used for
TIVA have a better protective effect on the platelet acti-
vation in this subgroup of patients.
The evaluation of markers detecting activation of the
hemostatic system represents a more sensitive way to
assess the risk of thromboembolism as compared to the
clinical assessment of TED. In our study, the activation of
haemostatic system associated with thromboembolic risk
was estimated by measuring levels of thrombin activation
markers. TAT, PF1 + 2 and FVIII increased in the immedi-
ate post operative period and gradually returned to near
baseline levels. The peri-operative activation of coagula-
tion also caused an increased of peri-operative PAI-1
levels, a potent inhibitor of fibrinolysis. The activation
state persists during surgery and is independent of the
anaesthetic agents used. These results confirm previous
studies performed on patients undergoing major abdominal
surgery for colon-rectal cancer [27], hepatic cancer resec-
tion [28], pneumonectomy for lung cancer [29].
No studies had previously examined whether different
intra-operative anaesthetic regimens (TIVA-TCI vs. BAL)
could cause different intra-operative profiles of highly
Table 4 Changes of prothrombotic markers in patients with prostate cancer who underwent surgery with balanced
inhalation anaesthesia (BAL) before the induction of anaesthesia (T0), 1 hr post-surgery (T1) and 24 hrs post-surgery (T2)
T0 T1 T2 P
T0 vs T1 T1 vs T2 T0 vs T2
Screening clotting time
- PT (%) 91.4 (1.4) 86.8 (1.6) 81.8 (1.4) 0.007 0.02 0.001
- PTT (sec) 30.1 (0.4) 26.2 (0.7) 28.3 (0.6) 0.001 0.02 0.01
Procoagulant markers
- Fibrinogen (mg/dL) 318.5 (8.6) 301.3 (10.9) 372.4 (11.2) 0.21 0.001 0.001
- TAT (ng/L) 6.2 (0.8) 19.2 (3.1) 6.7 (0.8) 0.002 0.002 0.42
- F1 + 2 (pmol/L) 182.4 (11.8) 558.1 (65.6) 266.8 (19.2) 0.001 0.001 0.001
- FVIII (%) 123.4 (4.8) 228.2 (15.8) 169.2 (6.2) 0.001 0.001 0.001
Fibrinolysis markers
- PAI-1 (ng/ml) 14.1 (1.4) 21.7 (15.8) 22.6 (2.4) 0.16 0.86 0.002
- D-dimer (μg/L) 175.5 (22.6) 622.1 (175.4) 421.3 (30.6) 0.003 0.07 0.001
Haemostatic system inhibitors
- AT (%) 97.8 (1.7) 92.0 (1.7) 89.1 (1.8) 0.04 0.25 0.001
- protein C (%) 105.2 (3.8) 99.3 (2.7) 88.5 (2.7) 0.18 0.03 0.001
- protein S (%) 95.6 (2.4) 91.2 (2.4) 81.8 (2.6) 0.08 0.01 0.001
Platelet-aggregating properties
- p-selectin (ng/ml) 41.5 (2.7) 40.7 (2.9) 40.2 (2.8) 0.65 0.88 0.18















Figure 3 Changes of p-selectin levels between T0 (before the
induction of anaesthesia) and T2 (24 hrs post-surgery) in patients
undergoing conventional laparoscopic radical prostatectomy
(LRP) or robot-assisted laparoscopic prostatectomy (RALP).
TIVA-TCI patients undergoing LRP showed a significant reduction in
p-selectin levels between T0 and T2 (p = 0.001) while no changes
were observed in the BAL group. In contrast, a significant increase of
p-selectin value was observed 24 hours after surgery (T2) in patients
undergoing RALP, regardless of the type of anaesthesia.
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in prostate cancer patients undergoing a highly standard-
ized type of surgery (LRP or RALP). In this context, the
results of our study seem to provide useful information
in reducing the peri-operative trombo-embolic risk and
improving the prognosis of cancer patients undergoing
LRP and RALP.
Even though cancer patients who undergo surgery are
targeted for thromboprophylaxis, widespread use of
prophylaxis could determine the risk of intra-operative
bleeding [23,24] and a detrimental effect rather than a
benefit. This problem is evident in prostate cancer
patients undergoing surgery, especially in view of the
increasingly frequent use of the robotic technique that
has resulted in a significant reduction of surgical compli-
cations [30,31]. Although the American and European
guidelines recommend prophylaxis in patients with pros-
tate cancer [18-22], its use is currently widely debated
given the different incidence of TED observed by several
authors. A multicentric analysis of a number of institutions
from both Europe and the United States showed a very low
incidence of TED (about 0.5%) [32]. A similar incidence
(0.9%) was reported from the California Cancer Registry
[4]. Conversely, Osborne et al. [14] consider patients with
prostate cancer at intermediate risk of TED similar to
patients with uterine, rectal, colon and liver cancer.
Prostatectomy significantly increases the incidence of
TED up to 2.9% and 3.9%, as reported by Hu JC et al.
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[33] in a recent meta-analysis on 400 original research
articles on surgical treatment for prostate cancer and its
complications reported that the rate of deep vein throm-
bosis was significantly lowest for RALP (0.3%), intermediate
for LRP (0.5%) and highest for open surgery (1.0%). More
recently, Van Hemelrijck et al. [16] analysed thrombo-
embolic events following prostatectomy in about 45.000
men collected in the Prostate Cancer Database Sweden.
Risk of venous thromboembolism and pulmonary embol-
ism occurred especially in the first 2 months after surgery
with the highest risk in patients undergoing open or laparo-
scopic surgery with pelvic lymph node dissection while
laparoscopic procedures without lymph node dissection
were at lowest risk. Unfortunately, in this study authors
did not created separate categories for LRP and RALP as
the majority of laparoscopic surgery was performed with
robotic assistance. In our case series, dissection of pelvic
lymph node was not an independent risk factor for TED
because no significant differences were demonstrated in
the values of the markers analyzed among the various
subgroups of patients studied. Moreover, it should be
noted that in previous studies only the clinical incidence
of venous thromboembolism was measured, but not the
changes of coagulation factors. In other studies many
biomarkers were specifically checked for their capacity
to predict venous thromboembolism during the course
of cancer disease [10], but changes in these markers due
to different types of surgery, such as LRP or RALP, were
not evaluated. Our results are even more surprising when
we consider that the anesthetic drugs used both in TIVA-
TCI and BAL, in particular propofol [34] and sevoflurane
[35], act by inhibiting the platelet aggregation, although
with different mechanisms.
Patients underwent RALP, compared to LRP group,
showed a greater reduction of inhibitors of haemostatic
system, such as protein S, and the increase of p-selectin,
a cell adhesion molecule on the surface of activated
endothelial cells and activated platelets [13]. Data present
in the literature regarding the different risk of thrombosis
in patients submitted to LRP or RALP are very few. In a
recent study Saily et al. [36] observed that RALP activates
coagulation, and thromboprophylaxis for high-risk patients
even after minimally invasive surgery may be beneficial. In
particular, patients undergoing RALP showed postopera-
tively increased levels of fibrinogen, factor VIII, d-dimer
associated to a thrombocytosis, reflecting a coagulation
activity. The greater risk of thrombosis with the RALP
could be also related to the surgical stress that leads RALP
to a major release of inflammatory mediators [37] or a
greater oxidative stress induced by ischemia–reperfusion
[38], determining the endothelial dysfunction and hyper-
coagulability [27]. This hypothesis is outlined by the
fact that no differences were observed in other factorsthat may cause an activation of the haemostatic system
in the peri-operative period such as anemia, hypoxia,
hypothermia, hemodilution, hypotension, peritoneal insuf-
flation, and Trendelenburg position [39,40]. We do not
know whether changes in pro-coagulant factors may
determine the occurrence of thrombotic complications
since an anti-thrombotic prophylaxis was administered
for ethical reasons 24 hrs after surgery.
Our results suggest the use of a prophylaxis in all
patients undergoing laparoscopic prostatectomy, in
particular RALP, regardless of the type of anesthesia.
Prophylaxis could not be required only in patients
undergoing LRP with TIVA-TCI anaesthesia since a
significant reduction in p-selectin levels between T0
and T2 (p = 0.001) was observed in this subgroup of
patients. On the contrary, p-selectin did not change in
patients undergoing LRP with BAL. Thus, the results we
obtained suggest a greater inhibition effect of propofol,
as compared to sevofluorane, on platelet aggregation p-
selectin mediated. The different effect of propofol and
sevofluorane on p-selectin levels observed in our study
is in agreement with previous observations reporting
that sevofluorane inhibits human platelet aggregation
induced by weak antagonists such as adenosine diphos-
phate, but not by strong agonists like thrombin [41,42].
Propofol, on the contrary, inhibits platelet aggregation
mediated by thrombin [43] that regulates also the expres-
sion of p-selectin on platelets.Conclusions
The marked and significant increase in pro-coagulant
factors and consequent reduction in haemostatic system
inhibitors we observed in the early post operative period
suggests that a peri-operative thromboprophylaxis may
be beneficial in cancer patients undergoing laparoscopic
radical prostatectomy especially when a robot-assistance
is used.
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